TW202344242A - Compositions and related methods for skin lightening - Google Patents
Compositions and related methods for skin lightening Download PDFInfo
- Publication number
- TW202344242A TW202344242A TW111117349A TW111117349A TW202344242A TW 202344242 A TW202344242 A TW 202344242A TW 111117349 A TW111117349 A TW 111117349A TW 111117349 A TW111117349 A TW 111117349A TW 202344242 A TW202344242 A TW 202344242A
- Authority
- TW
- Taiwan
- Prior art keywords
- composition
- acid
- skin
- vitamin
- weight percent
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 238000000034 method Methods 0.000 title claims abstract description 21
- 206010040829 Skin discolouration Diseases 0.000 title claims abstract description 6
- 210000003491 skin Anatomy 0.000 claims abstract description 58
- LBTVHXHERHESKG-UHFFFAOYSA-N tetrahydrocurcumin Chemical compound C1=C(O)C(OC)=CC(CCC(=O)CC(=O)CCC=2C=C(OC)C(O)=CC=2)=C1 LBTVHXHERHESKG-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000003112 inhibitor Substances 0.000 claims abstract description 24
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 20
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 20
- 239000000654 additive Substances 0.000 claims abstract description 17
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 17
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 230000008099 melanin synthesis Effects 0.000 claims abstract description 15
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 14
- AQIHDXGKQHFBNW-ZCFIWIBFSA-N (2r)-2-(4-hydroxyphenoxy)propanoic acid Chemical compound OC(=O)[C@@H](C)OC1=CC=C(O)C=C1 AQIHDXGKQHFBNW-ZCFIWIBFSA-N 0.000 claims abstract description 12
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 claims abstract description 12
- 210000000434 stratum corneum Anatomy 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000010521 absorption reaction Methods 0.000 claims abstract description 10
- 230000000996 additive effect Effects 0.000 claims abstract description 10
- 239000003623 enhancer Substances 0.000 claims abstract description 10
- SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims abstract description 9
- 229940093497 ergothioneine Drugs 0.000 claims abstract description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 7
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 7
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 7
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 7
- 108010024636 Glutathione Proteins 0.000 claims abstract description 7
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 7
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 7
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 7
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 7
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 7
- 229960003180 glutathione Drugs 0.000 claims abstract description 7
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 7
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims abstract description 5
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 5
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims abstract description 5
- 229940114124 ferulic acid Drugs 0.000 claims abstract description 5
- 235000001785 ferulic acid Nutrition 0.000 claims abstract description 5
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims abstract description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 5
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 5
- 229940046009 vitamin E Drugs 0.000 claims abstract description 5
- 239000011709 vitamin E Substances 0.000 claims abstract description 5
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims abstract description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 4
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims abstract description 4
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims abstract description 4
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 4
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims abstract description 4
- 229940117895 bakuchiol Drugs 0.000 claims abstract description 4
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims abstract description 4
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims abstract description 4
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 claims abstract description 4
- 229940093767 glabridin Drugs 0.000 claims abstract description 4
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 claims abstract description 4
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960004135 idebenone Drugs 0.000 claims abstract description 4
- JGPMMRGNQUBGND-UHFFFAOYSA-N idebenone Chemical compound COC1=C(OC)C(=O)C(CCCCCCCCCCO)=C(C)C1=O JGPMMRGNQUBGND-UHFFFAOYSA-N 0.000 claims abstract description 4
- 235000021283 resveratrol Nutrition 0.000 claims abstract description 4
- 229940016667 resveratrol Drugs 0.000 claims abstract description 4
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 4
- 239000011718 vitamin C Substances 0.000 claims abstract description 4
- 230000002087 whitening effect Effects 0.000 claims description 27
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 14
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
- 229960003512 nicotinic acid Drugs 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 229930003537 Vitamin B3 Natural products 0.000 claims description 8
- 229930003571 Vitamin B5 Natural products 0.000 claims description 8
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 8
- 229960002079 calcium pantothenate Drugs 0.000 claims description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 8
- 235000019160 vitamin B3 Nutrition 0.000 claims description 8
- 239000011708 vitamin B3 Substances 0.000 claims description 8
- 235000009492 vitamin B5 Nutrition 0.000 claims description 8
- 239000011675 vitamin B5 Substances 0.000 claims description 8
- 235000019441 ethanol Nutrition 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 6
- 208000003351 Melanosis Diseases 0.000 claims description 6
- 208000000069 hyperpigmentation Diseases 0.000 claims description 6
- 230000003810 hyperpigmentation Effects 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical class OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 5
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims description 4
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims description 4
- FCGXLCNBWYIEAA-UHFFFAOYSA-N 1,3-benzothiazol-6-ylmethanamine Chemical compound NCC1=CC=C2N=CSC2=C1 FCGXLCNBWYIEAA-UHFFFAOYSA-N 0.000 claims description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 claims description 4
- WWVBRUMYFUDEJQ-UHFFFAOYSA-N 1-ethoxyethane-1,2-diol Chemical compound CCOC(O)CO WWVBRUMYFUDEJQ-UHFFFAOYSA-N 0.000 claims description 4
- 208000027418 Wounds and injury Diseases 0.000 claims description 4
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims description 4
- 229940036350 bisabolol Drugs 0.000 claims description 4
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims description 4
- 235000019480 chamomile oil Nutrition 0.000 claims description 4
- 239000010628 chamomile oil Substances 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 150000003431 steroids Chemical class 0.000 claims description 4
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 3
- 206010004950 Birth mark Diseases 0.000 claims description 3
- 241000195940 Bryophyta Species 0.000 claims description 3
- 206010008570 Chloasma Diseases 0.000 claims description 3
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 206010014970 Ephelides Diseases 0.000 claims description 3
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 claims description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 claims description 3
- 206010039580 Scar Diseases 0.000 claims description 3
- 206010064127 Solar lentigo Diseases 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 206010000496 acne Diseases 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- 229960002255 azelaic acid Drugs 0.000 claims description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 150000002191 fatty alcohols Chemical class 0.000 claims description 3
- 150000002194 fatty esters Chemical class 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229960004275 glycolic acid Drugs 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960002510 mandelic acid Drugs 0.000 claims description 3
- 235000010446 mineral oil Nutrition 0.000 claims description 3
- 239000002480 mineral oil Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 229920001296 polysiloxane Polymers 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960004889 salicylic acid Drugs 0.000 claims description 3
- 231100000241 scar Toxicity 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 230000037370 skin discoloration Effects 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004383 yellowing Methods 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 239000007764 o/w emulsion Substances 0.000 claims description 2
- 230000008833 sun damage Effects 0.000 claims description 2
- 239000007762 w/o emulsion Substances 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000004378 Glycyrrhizin Substances 0.000 abstract 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract 1
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract 1
- 235000019410 glycyrrhizin Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 14
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 5
- 102000003425 Tyrosinase Human genes 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 2
- 101710200814 Melanotropin alpha Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 235000005811 Viola adunca Nutrition 0.000 description 2
- 240000009038 Viola odorata Species 0.000 description 2
- 235000013487 Viola odorata Nutrition 0.000 description 2
- 235000002254 Viola papilionacea Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- WPBWJEYRHXACLR-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O.OC(=O)CCCCCCCC(O)=O WPBWJEYRHXACLR-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- LUKBXSAWLPMMSZ-UHFFFAOYSA-N resveratrol Chemical compound C1=CC(O)=CC=C1C=CC1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- -1 skin protectants Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Abstract
Description
本發明係有關於一種護膚技術領域,尤指一種可有效減少黑色素產生藉以達到美白淡斑效果之用於皮膚美白之組合物、形成該組合物的方法、及皮膚美白的方法。The present invention relates to the technical field of skin care, and in particular, to a composition for skin whitening that can effectively reduce the production of melanin to achieve whitening and lightening effects, a method of forming the composition, and a method of skin whitening.
人體皮膚黑色素的形成起因於集中在表皮底層的黑色素細胞,當皮膚照射到紫外線,或是受到情緒、壓力或內分泌影響時,角質細胞會放出自由基,自由基是身體在維持生理機能中代謝產生的不穩定物質,它的活性極強,會主動與皮質中的物質行一系列氧化還原反應,進一步刺激末梢神經釋出介白素 (interleukin)、前列腺素(prostaglandin)等細胞激素,引起發炎反應,並促使腦下垂體分泌α黑色素細胞刺激素(α-melanocyte-stimulating hormon, α-MSH)。α-MSH會激活黑色素細胞內的酪胺酸酶活化,活化後的酪氨酸酶會與血液中的「酪氨酸」產生反應,經氧化作用而生成「多巴」經再次氧化後成為「多巴醌」,釋出黑色素與類黑色素;此時含有大量黑色素的黑色素體便藉由黑色素細胞的突觸把黑色素傳給周遭的角質細胞,以達到保護皮膚細胞的目的。接下來被釋放出的黑色素,會逐漸被送到表皮層,漸漸再移往表皮使皮膚變黑,最終被代謝掉。 因此,減少活性自由基刺激、抑制末梢神經作用,以及減緩介白素、前列腺素等造成的發炎反應或是抑制酪胺酸酶活性被視為減少黑色素產生(美白)的關鍵步驟。 是以,要如何解決上述習用之問題與缺失,即為從事此行業之相關廠商所亟欲研究改善之方向所在者。 The formation of melanin in human skin originates from melanocytes concentrated at the bottom of the epidermis. When the skin is exposed to ultraviolet rays, or is affected by emotions, stress or endocrine, keratinocytes will release free radicals. Free radicals are metabolized by the body in maintaining physiological functions. It is an unstable substance that is extremely active and will actively undergo a series of redox reactions with substances in the cortex, further stimulating peripheral nerves to release interleukin, prostaglandin and other cytokines, causing an inflammatory reaction. And prompts the pituitary gland to secrete α-melanocyte-stimulating hormon (α-MSH). α-MSH activates tyrosinase in melanocytes. The activated tyrosinase reacts with "tyrosine" in the blood and is oxidized to produce "dopa" which is oxidized again and becomes "dopa". Dopaquinone" releases melanin and melanoidin; at this time, melanosomes containing a large amount of melanin transfer melanin to surrounding keratinocytes through the synapses of melanocytes to protect skin cells. The melanin that is released next will be gradually sent to the epidermis, and then gradually moves to the epidermis to darken the skin, and is eventually metabolized. Therefore, reducing the stimulation of active free radicals, inhibiting the effects of peripheral nerves, slowing down the inflammatory reactions caused by interleukins, prostaglandins, etc., or inhibiting tyrosinase activity are considered key steps to reduce melanin production (whitening). Therefore, how to solve the above-mentioned conventional problems and deficiencies is the direction that relevant manufacturers in this industry are eager to study and improve.
爰此,為有效解決上述之問題,本發明之主要目的在於提供一種具有美白淡斑效果之用於皮膚美白之組合物、形成該組合物的方法、及皮膚美白的方法。 本發明之次要目的,在於提供一種具有抗氧化效果之用於皮膚美白之組合物、形成該組合物的方法、及皮膚美白的方法。 本發明之次要目的,在於提供一種可有效減少黑色素產生之用於皮膚美白之組合物、形成該組合物的方法、及皮膚美白的方法。 為達上述目的,本發明係提供一種用於皮膚美白之組合物,係包括至少一護膚品上或皮膚學上可接受之添加劑、一抗氧化劑、至少一發炎抑制劑、一黑色素生成抑制劑、一角質層代謝劑及一吸收促進劑,該抗氧化劑包含選自二種由以下所組成的群組:補骨脂酚(Bakuchiol)、維生素C(Vitamin C)、艾地苯(Idebenone)、輔酶Q10(coenzyme Q10)、維生素E(Vitamin E)、阿魏酸(ferulic acid)、白藜蘆醇(resveratrol)、麥角硫因(Ergothioneine)、鞣花酸(Ellagic acid)、穀胱甘肽(Glutathione)、壬二酸(Azelaic acid)、羥基苯氧基丙酸((R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA])、光甘草啶(Glabridin)、四氫薑黃素(Tetrahydrocurcumin; THC),及其組合。 在一實施例中,所述發炎抑制劑係選自由類固醇(steroid)、洋甘菊精(Chamomile Oil)、紅沒藥醇(Bisabolol)、維生素B5(Panthothenic Acid)其中任一或其組合,所述黑色素生成抑制劑係選自由維生素B3(nicotinic acid)、羥基苯氧基丙酸((R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA])其中任一或其組合,所述角質層代謝劑係選自由維生素A((Vitamin A)、甘醇酸(Glycolic Acid)、乳酸(Lactic Acid )、水楊酸(Salicylic acid)、杏仁酸(Mandelic Acid)、壬二酸(Azelaic acid)、維生素B5(Panthothenic Acid)其中任一或其組合,所述吸收促進劑係選自由乙醇(ethanol)、丙二醇(propylene glycol)、乙氧基乙二醇(ethoxydiglycol)、異山梨醇二甲基醚(Isosorbide Dimethyl Ether)、氮酮(Azone)其中任一或其組合。 在一實施例中,所述護膚品上或皮膚學上可接受添加劑係選自由以下所組成的群組:水、甘油、蠟、醇類、植物油、礦物油、矽酮、脂肪酯、脂肪醇、乙二醇、聚乙二醇、及其組合。 在一實施例中,所述組合物係包括0.01至0.03重量百分比的麥角硫因、0.01至3重量百分比的四氫薑黃素、1至3重量百分比的維生素B3、1至3重量百分比的維生素B5及2至5重量百分比的乙氧基乙二醇。 在一實施例中,進一步定義為用於施用在人體皮膚的一外用組合物。 在一實施例中,所述外用組合物的形式為一凝膠、一乳劑、一水中油滴乳液、一油中水型乳液、一泡沫、一液體、一慕思、一粉末、一固體、或適合外部施加在人體皮膚的一軟膏。 為達上述目的,本發明係提供一種形成該組合物的方法,該方法包含: 提供至少一護膚品上或皮膚學上可接受之添加劑; 提供一抗氧化劑、至少一發炎抑制劑、至少一黑色素生成抑制劑、至少一角質層代謝劑、至少一吸收促進劑;以及 結合該護膚品上或皮膚學上可接受之添加劑及該抗氧化劑、發炎抑制劑、黑色素生成抑制劑、角質層代謝劑、吸收促進劑以形成該組合物。 為達上述目的,本發明係提供該組合物於製備供一受試者的皮膚美白之外用組合物的用途,該用途包含: 提供該外用組合物;以及 將該外用組合物施加至該受試者的皮膚。 在一實施例中,所述外用組合物係至少每日一次塗覆至皮膚,持續一週或一週以上之時間期。 在一實施例中,其中遭受以下中之一或多者:皮膚黝黑、色素性皮膚變色、色素性胎記、色素過多、炎症後色素過多、損傷後色素過多、雀斑、老年斑、肝斑、太陽曬傷、曬黑、色素性痤瘡痕、疤痕、黑斑、黃褐斑、燒傷後疤痕、皮膚泛黃或黑眼圈。 藉由本發明的各種具體實施例,本發明的有益效果為:本發明的組合物麥角硫因、四氫薑黃素、維生素B3、維生素B5及乙氧基乙二醇,具有協同增效的作用,製備得到的組合物具有較强的DPPH清除能力、總還原力、抑制發炎、抑制黑色素小體轉移、抑制酪胺酸酶活性,進以大幅減少黑色素產生,此外,該組合物含有具有加速角質層代謝功效並輔以皮膚角質層滲透功效之原料,如此可達到抗氧化美白的功效,能用於製備抗氧化美白護膚品。 Therefore, in order to effectively solve the above problems, the main purpose of the present invention is to provide a composition for skin whitening with whitening and lightening effects, a method of forming the composition, and a method of skin whitening. The secondary purpose of the present invention is to provide a composition for skin whitening with antioxidant effect, a method of forming the composition, and a method of skin whitening. A secondary objective of the present invention is to provide a composition for skin whitening that can effectively reduce melanin production, a method for forming the composition, and a method for skin whitening. In order to achieve the above object, the present invention provides a composition for skin whitening, which includes at least one skin care product or dermatologically acceptable additive, an antioxidant, at least one inflammation inhibitor, and a melanin production inhibitor. A stratum corneum metabolism agent and an absorption enhancer, the antioxidant comprising two groups selected from the following: Bakuchiol, Vitamin C, Idebenone, coenzyme Q10 (coenzyme Q10), vitamin E (Vitamin E), ferulic acid (ferulic acid), resveratrol (resveratrol), ergothioneine (Ergothioneine), ellagic acid (Ellagic acid), glutathione ( Glutathione), Azelaic acid, (R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA]), Glabridin, Tetrahydroturmeric Tetrahydrocurcumin (THC), and combinations thereof. In one embodiment, the inflammation inhibitor is selected from any one of steroids, chamomile oil, bisabolol, panthothenic acid or a combination thereof, and the melanin The production inhibitor is selected from any one of vitamin B3 (nicotinic acid), hydroxyphenoxypropionic acid ((R)-2-(4-hydroxyphenoxy) propionic acid [(R)-HPOPA]) or a combination thereof, as described The stratum corneum metabolizing agent is selected from the group consisting of Vitamin A, Glycolic Acid, Lactic Acid, Salicylic acid, Mandelic Acid, and Azelaic acid. ), vitamin B5 (Panthothenic Acid) or any combination thereof, the absorption enhancer is selected from ethanol, propylene glycol, ethoxydiglycol, isosorbide dimethyl Ether (Isosorbide Dimethyl Ether), azone (Azone) any one or a combination thereof. In one embodiment, the skin care product or dermatologically acceptable additive is selected from the group consisting of: water, glycerin, wax, alcohol, vegetable oil, mineral oil, silicone, fatty ester, fatty alcohol , ethylene glycol, polyethylene glycol, and combinations thereof. In one embodiment, the composition includes 0.01 to 0.03 weight percent ergothioneine, 0.01 to 3 weight percent tetrahydrocurcumin, 1 to 3 weight percent vitamin B3, and 1 to 3 weight percent vitamin B3. B5 and 2 to 5 weight percent ethoxyethylene glycol. In one embodiment, it is further defined as a topical composition for application to human skin. In one embodiment, the external composition is in the form of a gel, an emulsion, an oil-in-water emulsion, a water-in-oil emulsion, a foam, a liquid, a mousse, a powder, a solid, or an ointment suitable for external application to human skin. In order to achieve the above object, the present invention provides a method for forming the composition, which method includes: Provide at least one skin care or dermatologically acceptable additive; Provide an antioxidant, at least one inflammation inhibitor, at least one melanin production inhibitor, at least one stratum corneum metabolizing agent, and at least one absorption enhancer; and The composition is combined with the skin care product or dermatologically acceptable additives and the antioxidant, inflammation inhibitor, melanin production inhibitor, stratum corneum metabolism agent, and absorption enhancer. In order to achieve the above object, the present invention provides the use of the composition in preparing a skin whitening external composition for a subject, and the use includes: providing the topical composition; and The topical composition is applied to the subject's skin. In one embodiment, the topical composition is applied to the skin at least once daily for a period of one week or more. In one embodiment, the patient suffers from one or more of the following: dark skin, pigmented skin discoloration, pigmented birthmark, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, freckles, age spots, liver spots, sun exposure Injuries, suntans, pigmented acne marks, scars, dark spots, chloasma, post-burn scars, yellowing of the skin or dark circles. Through various specific embodiments of the present invention, the beneficial effects of the present invention are: the composition of the present invention, ergothioneine, tetrahydrocurcumin, vitamin B3, vitamin B5 and ethoxyethylene glycol, has a synergistic effect , the prepared composition has strong DPPH scavenging ability, total reducing power, inhibits inflammation, inhibits the transfer of melanosomes, inhibits tyrosinase activity, thereby significantly reducing melanin production. In addition, the composition contains the ability to accelerate keratinization It is a raw material that has layer metabolism effect and is supplemented by the penetration effect of the skin stratum corneum. This can achieve the antioxidant whitening effect and can be used to prepare antioxidant whitening skin care products.
本發明之上述目的及其結構與功能上的特性,將依據所附圖式之較佳實施例予以說明。 在以下,針對本發明有關用於皮膚美白之組合物、形成該組合物的方法、及皮膚美白的方法之構成及技術內容等,列舉各種適用的實例並配合參照隨文所附圖式而加以詳細地説明;然而,本發明當然不是限定於所列舉之該等的實施例、圖式或詳細說明內容而已。 再者,熟悉此項技術之業者亦當明瞭:所列舉之實施例與所附之圖式僅提供參考與說明之用,並非用來對本發明加以限制者;能夠基於該等記載而容易實施之修飾或變更而完成之發明,亦皆視為不脫離本發明之精神與意旨的範圍內,當然該等發明亦均包括在本發明之申請專利範圍。 又,以下實施例所提到的方向用語,例如:「上」、「下」、「左」、「右」、「前」、「後」等,僅是參考附加圖示的方向。因此,使用的方向用語是用來說明,而並非用來限制本發明;再者,在下列各實施例中,相同或相似的元件將採用相同或相似的元件標號。 一種用於皮膚美白之組合物,係包括至少一護膚品上或皮膚學上可接受之添加劑、一抗氧化劑、至少一發炎抑制劑、一黑色素生成抑制劑、一角質層代謝劑及一吸收促進劑。 該護膚品上或皮膚學上可接受之添加劑,包含但不限於:香料;防腐劑;醇類(如乙醇、丙醇和苯甲醇);甘油;粘合劑;流動劑;三乙酸甘油酯;植物油(如氫化植物油);礦物油;水;矽酮(如矽油);二氧化矽;蠟(如巴西棕櫚蠟和蜂蠟);脂肪酯和脂肪醇;乙二醇和聚乙二醇;及其組合。進一步說明,該組合物可包含一或多種額外的成分,合適的添加劑包含本發明中已知的那些添加劑,其包含但不限於保濕劑、潤膚劑、乳化劑、表面活性劑、油、抽出物、皮膚保護劑、消毒劑、防腐劑、抗神經痛化合物、抗氧化劑、去角質劑、香料、顏料、填充劑、溶劑、媒介物、載體、本技術具一般知識者已知的其他類型的添加劑、及其組合,這些添加劑可單獨使用或組合使用,具體而言,選擇性的添加劑可為用於個人護理產品和化妝品中的任何類型,皆包含在內。 該抗氧化劑用於指具有清除自由基之功能的化合物、植物抽出物或材料組合,其係包含選自以下二種所組成的群組:補骨脂酚(Bakuchiol)、維生素C(Vitamin C)、艾地苯(Idebenone)、輔酶Q10(coenzyme Q10)、維生素E(Vitamin E)、阿魏酸(ferulic acid)、白藜蘆醇(resveratrol)、麥角硫因(Ergothioneine)、鞣花酸(Ellagic acid)、穀胱甘肽(Glutathione)、壬二酸(Azelaic acid)、羥基苯氧基丙酸((R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA])、光甘草啶(Glabridin)、四氫薑黃素(Tetrahydrocurcumin; THC),及其組合。 該發炎抑制劑係選自由類固醇(steroid)、洋甘菊精(Chamomile Oil)、紅沒藥醇(Bisabolol)、維生素B5(Panthothenic Acid)其中任一或其組合。 該黑色素生成抑制劑係選自由維生素B3(nicotinic acid)、羥基苯氧基丙酸((R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA])其中任一或其組合。 該角質層代謝劑係選自由維生素A((Vitamin A)、甘醇酸(Glycolic Acid)、乳酸(Lactic Acid )、水楊酸(Salicylic acid)、杏仁酸(Mandelic Acid)、壬二酸(Azelaic acid)、維生素B5(Panthothenic Acid)其中任一或其組合。 該吸收促進劑係選自由乙醇(ethanol)、丙二醇(propylene glycol)、乙氧基乙二醇(ethoxydiglycol)、異山梨醇二甲基醚(Isosorbide Dimethyl Ether)、氮酮(Azone)其中任一或其組合。 在本發明的最佳實施例中,該組合物的最佳組成係包括0.01至0.03重量百分比(%wt.)的麥角硫因、0.01至3重量百分比的四氫薑黃素、1至3重量百分比的維生素B3、1至3重量百分比的維生素B5,以及2至5重量百分比的乙氧基乙二醇,換句話說,於本發明中,最佳實施例的組合物具備了五種成分,並且每一成分分別具有不同的功效,此五種成分組成該組合物後而形成本發明之最佳實施態樣。 在各種具體實施例中,該組合物藉由外部施加在受試者的皮膚上,受試者通常為人,且可包含各種年齡層的男性和女性,需說明的是,本發明的方法/組合物不限於特定受試者。 該組合物可有各種形式,包含固體、凝膠和液體。舉例來說,可將組合物配製用以施用於受試者皮膚的凝膠、乳劑、乳液、軟膏、慕思、粉末或泡沫。在另一範例中,組合物可配製透過噴灑方式到受試者的皮膚上。此外,組合物也可配製成噴霧劑,如氣溶膠噴霧劑或泵式噴霧劑。在又一範例中,組合物還可配製供使用預濕紙巾來施用。在另一例子中,該組合物可配製成在受試者皮膚上磨擦的固體,類似於市面上之磨砂膏產品。 請參閱第1圖,為本發明形成該組合物的製備方法,首先,提供至少一護膚品上或皮膚學上可接受之添加劑(添加劑的成分已詳如段落25所述),接著提供抗氧化劑、發炎抑制劑、黑色素生成抑制劑、角質層代謝劑及吸收促進劑共五種不同功效之原料,最後,將前述添加劑及各種原料按配比混合均勻,即得本發明之組合物。 需說明的是,若選擇所述抗氧化劑中的四氫薑黃素(Tetrahydrocurcumin; THC)當做該組合物的其中一種抗氧化劑的話,四氫薑黃素就必須在所有原料混合後再將其加入。 接著,進一步說明本發明之組合物於製備供一受試者的皮膚美白之外用組合物的用途,該用途包含提供該外用組合物,並將該外用組合物施加至該受試者的皮膚上,更進一步說明,組合物可用以美白受試者的皮膚,如前所述,受試者通常為人,且可包含不同年齡的男性和女性,該組合物不限於特定的受試者或受試者上的皮膚位置。例如,個人可根據使用需求將組合物施用至其面部、頸部、手臂、手部、胸部、軀幹、腿部、腳部等或其任何組合,施用至皮膚的區域可能是色素過多或色素不足,例如,受試者的皮膚本身為黝黑、色素性皮膚變色、色素性胎記、色素過多、炎症後色素過多、損傷後色素過多、雀斑、老年斑、肝斑、太陽曬傷、曬黑、色素性痤瘡痕、疤痕、黑斑、黃褐斑、燒傷後疤痕、皮膚泛黃或黑眼圈等問題。 此外,該組合物可根據受試者的需求每天、一天數次施用,在本發明的方法中,施用(例如局部應用)的頻率可取決於若干因素,包含受試者期望的皮膚美白的程度。一般來說,使用頻率為每天一次或兩次施用該組合物,使用時間包含早晨及/或晚上。 請參閱第2圖,為本發明組合物和習知成分(谷胱甘肽及輔酶Q10)相比較後的DPPH清除率結果統計圖,DPPH (1,1-diphenyl-2-picrylhydrazyl)是一種穩定的自由基,當其溶於甲醇或乙醇中會呈現藍紫色,當加入的成分樣品可以和 DPPH 自由基直接反應,則會阻斷 DPPH 自由基的連鎖反應,這時候呈現藍紫色的DPPH溶液顏色會轉成澄清的黃色,這就表示加入的成分樣品具有捕捉 DPPH自由基的能力,而呈現的顏色愈淡,則表示捕捉DPPH自由基的能力愈強,也就表示此成分樣品的抗氧化能力越好,因此,由圖可知,該組合物具有相當強的DPPH自由基的捕捉能力。 請參閱第3圖,為受試者持續使用該組合物後的美白效果統計圖,本實施例提供十位受試者使用該組合物,以一天使用兩次並持續56天後,利用肌膚檢測儀分別在受使者使用第0天及第56天時測量臉頰部位的美白效果,如圖顯示,明顯可知該組合物確實可達到美白的功效。 綜上所述,本發明相較於習知具有下列優點: 1.具有美白淡斑效果; 2.具有抗氧化效果; 3.有效減少黑色素產生。 以上已將本發明做一詳細說明,惟以上所述者,僅為本發明之一較佳實施例而已,當不能限定本創作實施之範圍。即凡依本發明申請範圍所作之均等變化與修飾等,皆應仍屬本發明之專利涵蓋範圍。 The above objects and structural and functional characteristics of the present invention will be explained based on the preferred embodiments of the accompanying drawings. In the following, with regard to the composition and technical content of the composition for skin whitening, the method of forming the composition, and the skin whitening method of the present invention, various applicable examples are enumerated with reference to the accompanying drawings. Detailed description; however, the present invention is of course not limited to the enumerated embodiments, drawings or detailed descriptions. Furthermore, those familiar with this technology should also understand that the enumerated embodiments and attached drawings are only for reference and illustration, and are not intended to limit the present invention; it can be easily implemented based on these descriptions. Inventions completed by modifications or changes are deemed to be within the scope of the spirit and intention of the present invention. Of course, such inventions are also included in the patentable scope of the present invention. In addition, the directional terms mentioned in the following embodiments, such as "up", "down", "left", "right", "front", "back", etc., are only for reference to the directions shown in the attached figures. Therefore, the directional terms used are used to illustrate but not to limit the present invention; furthermore, in the following embodiments, the same or similar component numbers will be used for the same or similar components. A composition for skin whitening, including at least one skin care or dermatologically acceptable additive, an antioxidant, at least one inflammation inhibitor, a melanin production inhibitor, a cuticle metabolism agent and an absorption promoter agent. The skin care products or dermatologically acceptable additives include but are not limited to: fragrances; preservatives; alcohols (such as ethanol, propanol and benzyl alcohol); glycerin; adhesives; flow agents; triacetin; vegetable oils (such as hydrogenated vegetable oil); mineral oil; water; silicones (such as silicone oil); silicon dioxide; waxes (such as carnauba wax and beeswax); fatty esters and fatty alcohols; ethylene glycols and polyethylene glycols; and combinations thereof. Further stated, the composition may contain one or more additional ingredients. Suitable additives include those known in the present invention, including but not limited to humectants, emollients, emulsifiers, surfactants, oils, extractants, etc. agents, skin protectants, disinfectants, preservatives, anti-neuralgia compounds, antioxidants, exfoliants, fragrances, pigments, fillers, solvents, vehicles, carriers, and other types known to those of ordinary skill in the art. Additives, and combinations thereof, which may be used alone or in combination, and in particular optional additives of any type used in personal care products and cosmetics, are included. The antioxidant is used to refer to compounds, plant extracts or material combinations with the function of scavenging free radicals, which include a group selected from the following two: Bakuchiol, Vitamin C , Idebenone, coenzyme Q10, vitamin E, ferulic acid, resveratrol, ergothioneine, ellagic acid ( Ellagic acid), glutathione (Glutathione), azelaic acid (Azelaic acid), hydroxyphenoxypropionic acid ((R) -2- (4-hydroxyphenoxy) propionic acid [(R)-HPOPA]), light Glabridin, Tetrahydrocurcumin (THC), and combinations thereof. The inflammation inhibitor is selected from any one of steroids, chamomile oil, bisabolol, vitamin B5 (Panthothenic Acid) or a combination thereof. The melanin production inhibitor is selected from any one of vitamin B3 (nicotinic acid), hydroxyphenoxypropionic acid ((R)-2-(4-hydroxyphenoxy) propionic acid [(R)-HPOPA]) or a combination thereof. The stratum corneum metabolizing agent is selected from the group consisting of Vitamin A, Glycolic Acid, Lactic Acid, Salicylic acid, Mandelic Acid, and Azelaic acid. acid), vitamin B5 (Panthothenic Acid) any one or a combination thereof. The absorption accelerator is selected from any one of ethanol, propylene glycol, ethoxydiglycol, Isosorbide Dimethyl Ether, Azone or its combination. In the best embodiment of the present invention, the optimal composition of the composition includes 0.01 to 0.03 weight percent (%wt.) of ergothioneine, 0.01 to 3 weight percent of tetrahydrocurcumin, 1 to 3 weight percent percentage of vitamin B3, 1 to 3 weight percent of vitamin B5, and 2 to 5 weight percent of ethoxyethylene glycol. In other words, in the present invention, the composition of the best embodiment has five ingredients, Moreover, each component has a different effect respectively, and these five components form the composition to form the best implementation of the present invention. In various embodiments, the composition is applied externally to the skin of a subject. The subject is usually human and can include men and women of various ages. It should be noted that the method/ The compositions are not limited to particular subjects. The compositions may take a variety of forms, including solids, gels, and liquids. For example, the composition may be formulated as a gel, emulsion, lotion, ointment, mousse, powder, or foam for application to the skin of a subject. In another example, the composition may be formulated by spraying onto the skin of a subject. Additionally, the compositions may be formulated as a spray, such as an aerosol spray or a pump spray. In yet another example, the composition can also be formulated for application using pre-moistened wipes. In another example, the composition can be formulated as a solid that is rubbed on a subject's skin, similar to commercially available scrub products. Please refer to Figure 1, which shows the preparation method of the composition of the present invention. First, at least one skin care product or dermatologically acceptable additive is provided (the ingredients of the additive are detailed as described in paragraph 25), and then an antioxidant is provided. , inflammation inhibitor, melanin production inhibitor, stratum corneum metabolism agent and absorption enhancer, a total of five raw materials with different functions. Finally, the aforementioned additives and various raw materials are mixed evenly according to the proportion to obtain the composition of the present invention. It should be noted that if Tetrahydrocurcumin (THC) among the antioxidants is selected as one of the antioxidants in the composition, the Tetrahydrocurcumin must be added after all the raw materials are mixed. Next, the use of the composition of the present invention in preparing a skin whitening topical composition for a subject is further described. The use includes providing the topical composition and applying the topical composition to the skin of the subject. , to further illustrate, the composition can be used to whiten the skin of a subject. As mentioned above, the subject is usually a human and can include men and women of different ages. The composition is not limited to a specific subject or subject. The location of the skin on the subject. For example, an individual may apply the composition to their face, neck, arms, hands, chest, torso, legs, feet, etc., or any combination thereof, depending on the need for use. The composition may be applied to areas of the skin that may be hyperpigmented or hypopigmented. , for example, the subject's skin is inherently dark, pigmented skin discoloration, pigmented birthmarks, hyperpigmentation, post-inflammatory hyperpigmentation, post-injury hyperpigmentation, freckles, age spots, liver spots, sun damage, tanning, pigmented Problems such as acne marks, scars, dark spots, melasma, post-burn scars, yellowing of the skin or dark circles. In addition, the composition can be applied daily or several times a day according to the needs of the subject. In the methods of the invention, the frequency of application (eg, topical application) can depend on several factors, including the degree of skin whitening desired by the subject. . Generally, the frequency of application is once or twice daily, in the morning and/or evening. Please refer to Figure 2, which is a statistical chart of the DPPH clearance results of the composition of the present invention compared with conventional ingredients (glutathione and coenzyme Q10). DPPH (1,1-diphenyl-2-picrylhydrazyl) is a stable Free radicals, when dissolved in methanol or ethanol, will appear blue-violet. When the added component sample can react directly with DPPH free radicals, it will block the chain reaction of DPPH free radicals. At this time, the color of the DPPH solution will appear blue-violet. It will turn into a clear yellow, which means that the added component sample has the ability to capture DPPH free radicals. The lighter the color, the stronger the ability to capture DPPH free radicals, which means the antioxidant ability of this component sample. The better, therefore, as can be seen from the figure, the composition has a fairly strong ability to capture DPPH free radicals. Please refer to Figure 3, which is a statistical chart of the whitening effect after the subjects continued to use the composition. This example provides ten subjects to use the composition twice a day for 56 days, and then use skin testing. The instrument measured the whitening effect on the cheek area of the subject on the 0th day and the 56th day of use. As shown in the figure, it is obvious that the composition can indeed achieve the whitening effect. To sum up, the present invention has the following advantages compared with the conventional ones: 1. It has the effect of whitening and lightening spots; 2. Has antioxidant effect; 3. Effectively reduce melanin production. The present invention has been described in detail above. However, the above description is only one of the preferred embodiments of the present invention and cannot limit the scope of the present invention. That is to say, all equivalent changes and modifications made according to the application scope of the present invention should still fall within the scope of the patent of the present invention.
S1~S3:步驟S1~S3: steps
第1圖為本發明組合物之製備步驟流程圖; 第2圖為本發明組合物和習知成分相比較後的DPPH清除率結果統計圖; 第3圖為受試者持續使用該組合物後的美白效果統計圖。 Figure 1 is a flow chart of the preparation steps of the composition of the present invention; Figure 2 is a statistical graph showing the DPPH clearance results of the composition of the present invention compared with conventional ingredients; Figure 3 is a statistical graph of the whitening effect after the subjects continued to use the composition.
S1~S3:步驟 S1~S3: steps
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111117349A TW202344242A (en) | 2022-05-09 | 2022-05-09 | Compositions and related methods for skin lightening |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW111117349A TW202344242A (en) | 2022-05-09 | 2022-05-09 | Compositions and related methods for skin lightening |
Publications (1)
Publication Number | Publication Date |
---|---|
TW202344242A true TW202344242A (en) | 2023-11-16 |
Family
ID=89720279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111117349A TW202344242A (en) | 2022-05-09 | 2022-05-09 | Compositions and related methods for skin lightening |
Country Status (1)
Country | Link |
---|---|
TW (1) | TW202344242A (en) |
-
2022
- 2022-05-09 TW TW111117349A patent/TW202344242A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI679992B (en) | A topical lightening composition and methods of use thereof | |
Liu | Natural products in cosmetics | |
KR101823036B1 (en) | Inhibitor of melanin synthesis and the cosmetic composition containing the same | |
KR20120083943A (en) | Composition of skin external application containing propanoid derivatives | |
US20100029784A1 (en) | Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties | |
KR20130035325A (en) | External composition for skin containing saponin derived from the root of camellia sinensis | |
EP2572701A2 (en) | Compositions comprising a retinoid and an NFkB-Inhibitor and their methods of use | |
KR20090130801A (en) | Composition for applying to skin externally containing extract from seeds of ginseng | |
EP3145480B1 (en) | Extemporaneous cosmetic and/or dermatologic compositions | |
KR101382112B1 (en) | Composition of skin external application containing Chamaecyparis obtusa polysaccharide | |
JP2023165989A (en) | Method of treating state associated with acne and/or hyperkeratinization | |
KR20090129928A (en) | Composition for applying to skin externally containing extract from flower of ginseng | |
KR20160120355A (en) | Skin-brightening cosmetic composition | |
Lourith et al. | Formulation and clinical evaluation of the standardized Litchi chinensis extract for skin hyperpigmentation and aging treatments | |
US11918666B2 (en) | Topical formulations comprising strontium and methylsulfonylmethane (MSM) and methods of treatment | |
KR20130031988A (en) | Skin external composition containing floral ginsenoside | |
KR102286679B1 (en) | External composition for skin containing an enzyme-treated saponin fraction derived from the root of Camellia sinensis | |
KR20120068707A (en) | Compositions comprising lilium martagon extracts and uses thereof | |
KR20190071250A (en) | Composition for whitening and moisturizing skin | |
KR101247153B1 (en) | A Cosmetic composition containing Acerola extract powder coated with silicone oil mixture | |
EP3620213A1 (en) | Retinol oil composition | |
TW202344242A (en) | Compositions and related methods for skin lightening | |
KR20130115482A (en) | Skin external composition comprising germinated camellia sinensis seed extract | |
TWM631195U (en) | Container structure for skin lightening care products | |
KR101179308B1 (en) | Composition for skin-whitener containing saponified evening primrose seed oil as an effective ingredient |